Literature DB >> 11916535

Alteration of drug biotransformation and elimination during infection and inflammation.

K W Renton1.   

Abstract

During infection or inflammation, the expression of cytochrome P450 and its dependent biotransformation pathways are modified. This results in a change in the capacity of the liver to handle drugs and in alterations in the production and elimination of endogenous substances throughout the body. The majority of the CYP isoforms are modified at pre-translational steps in protein synthesis, and, in most cases, cytokines are involved as mediators of the response. Recent information suggests that inflammatory responses that are localized to the CNS cause a loss of CYP within the brain. This is accompanied by a parallel down-regulation of CYP in peripheral organs that is mediated by a signaling pathway between the brain and periphery. This review covers the loss that occurs in the major mammalian CYP families in response to infection/inflammation and the mediator pathways that are key to this response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916535     DOI: 10.1016/s0163-7258(01)00165-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  36 in total

1.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

Review 2.  Noscapine may increase the effect of warfarin.

Authors:  Staffan Ohlsson; Lennart Holm; Olle Myrberg; Anders Sundström; Qun-Ying Yue
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

3.  Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.

Authors:  Gudrun Hefner; Mohamed E E Shams; Stefan Unterecker; Tanja Falter; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 4.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 5.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

6.  Treprostinil Improves Hepatic Cytochrome P450 Activity during Rat Liver Transplantation.

Authors:  Nisanne Ghonem; Junichi Yoshida; Noriko Murase; Stephen C Strom; Raman Venkataramanan
Journal:  J Clin Exp Hepatol       Date:  2012-10-12

7.  Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats.

Authors:  V G N V Prasad; Ch Vivek; P Anand Kumar; P Ravi Kumar; G S Rao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-20       Impact factor: 2.441

8.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

9.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models.

Authors:  Jun Zhang; Madhusudana R Chaluvadi; Rob Reddy; Meike S Motika; Terrilyn A Richardson; John R Cashman; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2008-12-16       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.